Leukemia in China
Overview
Leukemia is a cancer of blood-forming cells in the marrow, producing abnormal white cells that crowd out healthy blood production. It spans acute forms requiring urgent treatment and chronic forms managed over years with targeted drugs.
China’s hematology centers treat very large leukemia populations with full diagnostic platforms, induction protocols and transplant programs, alongside domestically developed targeted agents for specific mutations.
Symptoms & Signs
Fatigue, weakness and pallor from anemia
Fever and recurrent infections from neutropenia
Easy bruising, gum or nose bleeding from low platelets
Bone or joint pain from marrow expansion
Weight loss, night sweats and loss of appetite
Some chronic leukemias are discovered on routine blood counts long before symptoms
Diagnosis
Complete blood count with differential revealing abnormal cells or counts
Bone marrow aspiration and biopsy with morphology and flow cytometry
Cytogenetics and molecular testing — BCR-ABL, PML-RARA, FLT3, NPM1 and more — guiding precise classification
Next-generation sequencing panels detecting actionable mutations
Lumbar puncture checking for central-nervous-system involvement in acute leukemia
HLA typing performed early in case transplant becomes necessary
Treatment Options
Induction chemotherapy aiming for complete remission in acute leukemia
Targeted therapy: tyrosine-kinase inhibitors for CML and Ph+ ALL, all-trans retinoic acid with arsenic for APL
Consolidation and maintenance chemotherapy courses
Allogeneic hematopoietic stem-cell transplantation for high-risk or relapsed disease
Immunotherapy including CAR-T for B-cell acute lymphoblastic leukemia
Supportive care: transfusion, infection management and tumor-lysis prevention
Advanced Technologies & Novel Drug
Next-generation sequencing and flow cytometry minimal-residual-disease monitoring
Domestically developed FLT3 and BCL-2 inhibitor-class agents
Haplotype-identical transplant protocols pioneered at Chinese transplant centers
CAR-T programs for relapsed refractory B-ALL
Novel targeted agents for mutated AML and post-transplant maintenance
Hospital & Specialist
- Peking University People's Hospital — Beijing
- Hospital of Hematology, Chinese Academy of Medical Sciences — Tianjin
- Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine — Shanghai
- Peking University First Hospital (PKUHSC) — Beijing
- Wang Jian Xiang — Leukemia Diagnosis and Treatment Center
- Liu Bing Cheng — Leukemia Diagnosis and Treatment Center
- Mi Ying Chang — Leukemia Diagnosis and Treatment Center
- Wei Hui — Leukemia Diagnosis and Treatment Center